Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Tacke, Frank ^a   Kanig, Nicolas ^a,b   En Nia, Abdelaziz ^b   Kaehne, Thilo ^b   Eberhardt, Christiane S ^b   Shpacovitch, Victoria ^b   Trautwein, Christian ^a   Mertens, Peter R ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Cancer screening; Cold Shock Proteins; Hepatocellular carcinoma; Liver transplantation; Serum markers

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARRIER PROTEIN; COLD SHOCK PROTEIN; MONOCLONAL ANTIBODY; PROTEIN P18; TUMOR MARKER; Y BOX BINDING PROTEIN 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER SCREENING; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; FALSE POSITIVE RESULT; FEMALE; HUMAN; IMMUNOBLOTTING; INFLAMMATORY DISEASE; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; NEUROENDOCRINE TUMOR; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; ADOLESCENT; AMINO ACID SEQUENCE; BLOOD; CHRONIC DISEASE; INFLAMMATION; LIVER DISEASE; LIVER TUMOR; MIDDLE AGED; MOLECULAR GENETICS; SEQUENCE ALIGNMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; FEMALE; HUMANS; INFLAMMATION; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RENAL INSUFFICIENCY; SENSITIVITY AND SPECIFICITY; SEQUENCE ALIGNMENT; TUMOR MARKERS, BIOLOGICAL; Y-BOX-BINDING PROTEIN 1; YOUNG ADULT;

EID: 79956211688     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-185     Document Type: Article

References (42)

1. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dorken B, Royer HD. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997, 3(4):447-450. 10.1038/nm0497-447, 9095180.
2. Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D, Leenders F, Claude JC, Theuring F, Bargou R, Dietel M, Royer HD. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005, 65(10):4078-4087. 10.1158/0008-5472.CAN-04-4056, 15899797.
3. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, Schmitt M, Royer HD. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002, 97(3):278-282. 10.1002/ijc.1610, 11774277.
4. Huang X, Ushijima K, Komai K, Takemoto Y, Motoshima S, Kamura T, Kohno K. Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol 2004, 93(2):287-291. 10.1016/j.ygyno.2004.01.040, 15099935.
5. Yahata H, Kobayashi H, Kamura T, Amada S, Hirakawa T, Kohno K, Kuwano M, Nakano H. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol 2002, 128(11):621-626. 10.1007/s00432-002-0386-6, 12458343.
6. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K, Kuwano M. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001, 7(10):3151-3155.
7. Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, Iwamoto Y, Kohno K, Kuwano M, Tsuneyoshi M. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 2003, 199(2):251-258. 10.1002/path.1282, 12533839.
8. Yasen M, Kajino K, Kano S, Tobita H, Yamamoto J, Uchiumi T, Kon S, Maeda M, Obulhasim G, Arii S, Hino O. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res 2005, 11(20):7354-7361. 10.1158/1078-0432.CCR-05-1027, 16243807.
9. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003, 25(7):691-698. 10.1002/bies.10300, 12815724.
10. En-Nia A, Yilmaz E, Klinge U, Lovett DH, Stefanidis I, Mertens PR. Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem 2005, 280(9):7702-7711.
11. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks CB, Dunn SE. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 2006, 66(9):4872-4879. 10.1158/0008-5472.CAN-05-3561, 16651443.
12. Stenina OI, Shaneyfelt KM, DiCorleto PE. Thrombin induces the release of the Y-box protein dbpB from mRNA: a mechanism of transcriptional activation. Proc Natl Acad Sci USA 2001, 98(13):7277-7282. 10.1073/pnas.121592298, 34659, 11390977.
13. Mertens PR, Steinmann K, Alfonso-Jaume MA, En-Nia A, Sun Y, Lovett DH. Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells. J Biol Chem 2002, 277(28):24875-24882. 10.1074/jbc.M200445200, 11973333.
14. Lasham A, Lindridge E, Rudert F, Onrust R, Watson J. Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene 2000, 252(1-2):1-13. 10.1016/S0378-1119(00)00220-1, 10903433.
15. Berquin IM, Pang B, Dziubinski ML, Scott LM, Chen YQ, Nolan GP, Ethier SP. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 2005, 24(19):3177-3186. 10.1038/sj.onc.1208504, 15735691.
16. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009, 15(5):402-415. 10.1016/j.ccr.2009.03.017, 19411069.
17. Lasham A, Moloney S, Hale T, Homer C, Zhang YF, Murison JG, Braithwaite AW, Watson J. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem 2003, 278(37):35516-35523. 10.1074/jbc.M303920200, 12835324.
18. To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J, Astanehe A, Davies AH, Lee L, Stratford AL, Raouf A, Johnson P, Berquin IM, Royer HD, Eaves CJ, Dunn SE. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 2010, 70(7):2840-2851. 10.1158/0008-5472.CAN-09-3155, 2848879, 20332234.
19. Frye BC, Halfter S, Djudjaj S, Muehlenberg P, Weber S, Raffetseder U, En-Nia A, Knott H, Baron JM, Dooley S, Bernhagen J, Mertens PR. Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Rep 2009, 10(7):783-789. 10.1038/embor.2009.81, 2690452, 19483673.
20. Raffetseder U, Rauen T, Djudjaj S, Kretzler M, En-Nia A, Tacke F, Zimmermann HW, Nelson PJ, Frye BC, Floege J, Stefanidis I, Weber C, Mertens PR. Differential regulation of chemokine CCL5 expression in monocytes/macrophages and renal cells by Y-box protein-1. Kidney Int 2009, 75(2):185-196. 10.1038/ki.2008.457, 18800033.
21. Tacke F, Wustefeld T, Horn R, Luedde T, Srinivas Rao A, Manns MP, Trautwein C, Brabant G. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005, 42(5):666-673. 10.1016/j.jhep.2004.12.024, 15826715.
22. Yagmur E, Weiskirchen R, Gressner AM, Trautwein C, Tacke F. Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. Diabetes Care 2007, 30(5):1168-1172. 10.2337/dc06-2323, 17337499.
23. Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E, Fuchs T, Wild PJ, Hartmann A, Dunn SE, Mertens PR. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer 2009, 9:410. 10.1186/1471-2407-9-410, 2788584, 19930682.
24. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Analytical chemistry 1996, 68(5):850-858. 10.1021/ac950914h, 8779443.
25. Tacke F, Brabant G, Kruck E, Horn R, Schoffski P, Hecker H, Manns MP, Trautwein C. Ghrelin in chronic liver disease. J Hepatol 2003, 38(4):447-454. 10.1016/S0168-8278(02)00438-5, 12663236.
26. Yagmur E, Trautwein C, Gressner AM, Tacke F. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol 2006, 101(6):1244-1252. 10.1111/j.1572-0241.2006.00543.x, 16771945.
27. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl 1):S113-119.
28. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006, 26(4):385-390. 10.1055/s-2006-951606, 17051452.
29. Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers 2000, 15(3):226-230.
30. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2006,
31. Collazos J, Genolla J, Ruibal A. Evaluation of the behavior of carcinoembryonic antigen in cirrhotic patients. Int J Biol Markers 1992, 7(4):244-248.
32. Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 1998, 35(Pt 1):99-103.
33. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol 2007, 102(1):107-114. 10.1111/j.1572-0241.2006.00872.x, 17037993.
34. Tacke F, Fiedler K, von Depka M, Luedde T, Hecker H, Manns MP, Ganser A, Trautwein C. Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease. Liver Int 2006, 26(2):173-181. 10.1111/j.1478-3231.2005.01205.x, 16448455.
35. Duffy MJ. Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med 2007, 18(3):175-184. 10.1016/j.ejim.2006.12.001, 17449388.
36. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004, 350(22):2239-2246. 10.1056/NEJMoa031918, 15163773.
37. Tao LY, Cai L, He XD, Liu W, Qu Q. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg 2010, 76(11):1210-1213.
38. Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008, 8:200. 10.1186/1471-2407-8-200, 2488355, 18638391.
39. Bachtiar I, Santoso JM, Atmanegara B, Gani RA, Hasan I, Lesmana LA, Sulaiman A, Gu J, Tai S. Combination of alpha-1-acid glycoprotein and alpha-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma. Clin Chim Acta 2009, 399(1-2):97-101. 10.1016/j.cca.2008.09.024, 18926809.
40. Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 2010, 45(12):1272-1282. 10.1007/s00535-010-0278-5, 20625772.
41. Nomura F, Koyama A, Ishijima M, Takano S, Narita M, Nakai T. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure. Oncol Rep 1998, 5(2):389-392.
42. Filella X, Cases A, Molina R, Jo J, Bedini JL, Revert L, Ballesta AM. Tumor markers in patients with chronic renal failure. Int J Biol Markers 1990, 5(2):85-88.